Total Payments
$3,838
2024 Payments
$1,989
Companies
19
Transactions
47
Medicare Patients
2,631
Medicare Billing
$268,929
Payment Breakdown by Category
Research$2,442 (63.6%)
Food & Beverage$1,340 (34.9%)
Education$56.21 (1.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2,442 | 2 | 63.6% |
| Food and Beverage | $1,340 | 42 | 34.9% |
| Education | $56.21 | 3 | 1.5% |
Payments by Type
Research
$2,442
2 transactions
General
$1,396
45 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $2,442 | 2 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $329.28 | 4 | $0 (2023) |
| Regeneron Healthcare Solutions, Inc. | $224.30 | 3 | $0 (2024) |
| Enterra Medical, Inc. | $145.37 | 1 | $0 (2024) |
| PFIZER INC. | $133.62 | 4 | $0 (2018) |
| Merck Sharp & Dohme Corporation | $127.65 | 5 | $0 (2019) |
| Janssen Biotech, Inc. | $95.35 | 8 | $0 (2024) |
| ABBVIE INC. | $90.77 | 5 | $0 (2024) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $49.76 | 3 | $0 (2024) |
| Intercept Pharmaceuticals, Inc. | $48.64 | 2 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,989 | 10 | Eli Lilly and Company ($1,582) |
| 2023 | $971.71 | 8 | Eli Lilly and Company ($859.89) |
| 2022 | $94.19 | 1 | Regeneron Healthcare Solutions, Inc. ($94.19) |
| 2020 | $11.69 | 1 | Janssen Pharmaceuticals, Inc ($11.69) |
| 2019 | $327.20 | 10 | Janssen Scientific Affairs, LLC ($225.39) |
| 2018 | $382.44 | 14 | PFIZER INC. ($120.16) |
| 2017 | $61.31 | 3 | Intercept Pharmaceuticals, Inc. ($37.14) |
All Payment Transactions
47 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/06/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $21.36 | General |
| Category: Gastroenterology | ||||||
| 10/23/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | TRULANCE (Drug) | Food and Beverage | In-kind items and services | $17.31 | General |
| Category: Gastroenterology | ||||||
| 10/14/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $27.09 | General |
| Category: IMMUNOLOGY | ||||||
| 09/11/2024 | ABBVIE INC. | LINZESS (Drug), CREON | Food and Beverage | In-kind items and services | $18.75 | General |
| Category: GASTROENTEROLOGY | ||||||
| 07/19/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $107.95 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 06/12/2024 | ABBVIE INC. | CREON (Drug), LINZESS | Food and Beverage | In-kind items and services | $19.20 | General |
| Category: ENDOCRINOLOGY | ||||||
| 04/15/2024 | Enterra Medical, Inc. | — | Food and Beverage | In-kind items and services | $145.37 | General |
| 04/08/2024 | Janssen Biotech, Inc. | STELARA (Biological) | Food and Beverage | In-kind items and services | $33.36 | General |
| Category: Immunology | ||||||
| 03/06/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $16.92 | General |
| Category: Neuroscience | ||||||
| 01/08/2024 | Eli Lilly and Company | — | — | In-kind items and services | $1,581.88 | Research |
| Study: A MULTICENTER, PHASE 3B, OPEN-LABEL, SINGLE-ARM STUDY TO INVESTIGATE BOWEL URGENCY AND ITS RELATIONSHIP WITH OTHER OUTCOME MEASURES IN ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH MIRIKIZUMAB | ||||||
| 09/14/2023 | Janssen Biotech, Inc. | STELARA (Biological) | Food and Beverage | In-kind items and services | $12.81 | General |
| Category: Immunology | ||||||
| 09/11/2023 | Eli Lilly and Company | — | — | In-kind items and services | $859.89 | Research |
| Study: A MULTICENTER PHASE 3B OPEN-LABEL SINGLE-ARM STUDY TO INVESTIGATE BOWEL URGENCY AND ITS RELATIONSHIP WITH OTHER OUTCOME MEASURES IN ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH MIRIKIZUMAB | ||||||
| 07/23/2023 | RedHill Biopharma Inc. | Talicia (Drug), Movantik | Food and Beverage | In-kind items and services | $14.73 | General |
| Category: Antibiotic | ||||||
| 06/26/2023 | Amgen Inc. | AMJEVITA (Biological) | Food and Beverage | In-kind items and services | $15.21 | General |
| Category: Inflammation | ||||||
| 05/17/2023 | NESTLE HEALTHCARE NUTRITION INC. | VOWST (Biological) | Food and Beverage | In-kind items and services | $17.78 | General |
| Category: GI | ||||||
| 03/22/2023 | AbbVie Inc. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $14.79 | General |
| Category: IMMUNOLOGY | ||||||
| 03/01/2023 | Janssen Scientific Affairs, LLC | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $14.34 | General |
| Category: Immunology | ||||||
| 02/27/2023 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Education | In-kind items and services | $22.16 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 07/20/2022 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $94.19 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 03/09/2020 | Janssen Pharmaceuticals, Inc | — | Education | In-kind items and services | $11.69 | General |
| 11/21/2019 | Janssen Scientific Affairs, LLC | STELARA (Biological) | Food and Beverage | In-kind items and services | $122.08 | General |
| Category: Immunology | ||||||
| 10/25/2019 | Shire North American Group Inc | GATTEX (Drug) | Education | In-kind items and services | $22.36 | General |
| Category: INTERNAL MEDICINE | ||||||
| 09/10/2019 | Romark Laboratories, LC | Alinia (Drug), Alinia, Alinia | Food and Beverage | Cash or cash equivalent | $9.81 | General |
| Category: Gastroenterology | ||||||
| 07/11/2019 | QOL Medical, LLC | Sucraid (Drug) | Food and Beverage | Cash or cash equivalent | $15.43 | General |
| Category: THERAPY FOR CSID | ||||||
| 04/11/2019 | Merck Sharp & Dohme Corporation | DIFICID (Drug), ZINPLAVA | Food and Beverage | In-kind items and services | $12.35 | General |
| Category: INFECTIOUS DISEASE | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A MULTICENTER, PHASE 3B, OPEN-LABEL, SINGLE-ARM STUDY TO INVESTIGATE BOWEL URGENCY AND ITS RELATIONSHIP WITH OTHER OUTCOME MEASURES IN ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH MIRIKIZUMAB | Eli Lilly and Company | $1,582 | 1 |
| A MULTICENTER PHASE 3B OPEN-LABEL SINGLE-ARM STUDY TO INVESTIGATE BOWEL URGENCY AND ITS RELATIONSHIP WITH OTHER OUTCOME MEASURES IN ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH MIRIKIZUMAB | Eli Lilly and Company | $859.89 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 11 | 583 | 646 | $385,845 | $60,236 |
| 2022 | 14 | 654 | 739 | $344,992 | $67,484 |
| 2021 | 16 | 683 | 767 | $355,259 | $70,028 |
| 2020 | 13 | 711 | 957 | $351,455 | $71,181 |
Total Patients
2,631
Total Services
3,109
Medicare Billing
$268,929
Procedure Codes
54
All Medicare Procedures & Services
54 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 142 | 163 | $54,931 | $13,617 | 24.8% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 68 | 68 | $86,447 | $11,690 | 13.5% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 81 | 81 | $76,076 | $7,871 | 10.3% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 100 | 108 | $72,316 | $7,035 | 9.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 49 | 83 | $19,090 | $4,909 | 25.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 45 | 45 | $20,835 | $4,535 | 21.8% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2023 | 26 | 26 | $23,036 | $4,296 | 18.6% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 31 | 31 | $13,516 | $3,023 | 22.4% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2023 | 13 | 13 | $11,518 | $2,259 | 19.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 11 | 11 | $2,530 | $518.77 | 20.5% |
| 43450 | Dilation of esophagus | Facility | 2023 | 17 | 17 | $5,550 | $482.08 | 8.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 171 | 207 | $53,505 | $17,569 | 32.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 88 | 88 | $35,490 | $9,466 | 26.7% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2022 | 46 | 46 | $57,737 | $8,536 | 14.8% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 65 | 65 | $60,648 | $6,795 | 11.2% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 83 | 86 | $56,872 | $5,569 | 9.8% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 40 | 86 | $15,732 | $4,698 | 29.9% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2022 | 24 | 24 | $21,264 | $4,088 | 19.2% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 33 | 33 | $11,716 | $3,356 | 28.6% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2022 | 14 | 14 | $12,404 | $2,273 | 18.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 16 | 16 | $4,915 | $1,792 | 36.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 26 | 26 | $5,090 | $1,582 | 31.1% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 15 | 15 | $4,059 | $1,146 | 28.2% |
| 43450 | Dilation of esophagus | Facility | 2022 | 17 | 17 | $5,016 | $547.30 | 10.9% |
| 82272 | Stool analysis for blood, by peroxidase activity | Office | 2022 | 16 | 16 | $544.00 | $67.20 | 12.4% |
About Dr. John Roddey, M.D
Dr. John Roddey, M.D is a Gastroenterology healthcare provider based in Charlotte, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/04/2006. The National Provider Identifier (NPI) number assigned to this provider is 1619925419.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Roddey, M.D has received a total of $3,838 in payments from pharmaceutical and medical device companies, with $1,989 received in 2024. These payments were reported across 47 transactions from 19 companies. The most common payment nature is "" ($2,442).
As a Medicare-enrolled provider, Roddey has provided services to 2,631 Medicare beneficiaries, totaling 3,109 services with total Medicare billing of $268,929. Data is available for 4 years (2020–2023), covering 54 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Location Charlotte, NC
- Active Since 05/04/2006
- Last Updated 04/04/2012
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1619925419
Products in Payments
- STELARA (Biological) $401.96
- DUPIXENT (Biological) $224.30
- DIFICID (Drug) $112.72
- XELJANZ (Drug) $110.16
- OCA (Drug) $37.14
- RINVOQ (Biological) $27.09
- Alinia (Drug) $26.39
- INFLECTRA (Biological) $23.46
- GATTEX (Drug) $22.36
- XIFAXAN (Drug) $21.36
- CREON (Drug) $19.20
- LINZESS (Drug) $18.75
- VOWST (Biological) $17.78
- TRULANCE (Drug) $17.31
- ZEPOSIA (Drug) $16.92
- Sucraid (Drug) $15.43
- AMJEVITA (Biological) $15.21
- SKYRIZI (Biological) $14.79
- Talicia (Drug) $14.73
- TREMFYA (Drug) $14.34
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in Charlotte
Stephen Deal, M.d, M.D
Gastroenterology — Payments: $1.3M
Gastroenterology $1.3M
Fred Fowler, M.d, M.D
Gastroenterology — Payments: $873,591
Gastroenterology $873,591
Nilesh Lodhia, Md, MD
Gastroenterology — Payments: $807,140
Gastroenterology $807,140
Oscar Brann, M.d, M.D
Gastroenterology — Payments: $246,482
Gastroenterology $246,482
Maithili Chitnavis, Md, MD
Gastroenterology — Payments: $179,660
Gastroenterology $179,660
Dr. Kent Holtzmuller, Md, MD
Gastroenterology — Payments: $160,162
Gastroenterology $160,162